Unmet Needs in Dermatology: EC Approves Mirdametinib (Ezmekly, SpringWorks Therapeutics, Inc.) for NF1-PN in Children and Adults July 21, 2025
U.S. FDA Accepts Supplemental New Drug Application for Deucravacitinib (Sotyktu, Bristol Myers Squibb) in PsA July 21, 2025